Skip to main content
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2020 Dec 13;34(1):e14578. doi: 10.1111/dth.14578

Oral manifestations of COVID‐19 disease: A review article

Behzad Iranmanesh 1, Maryam Khalili 1, Rezvan Amiri 1, Hamed Zartab 1, Mahin Aflatoonian 2,
PMCID: PMC7744903  PMID: 33236823

Abstract

Dysgeusia is the first recognized oral symptom of novel coronavirus disease (COVID‐19). In this review article, we described oral lesions of COVID‐19 patients. We searched PubMed library and Google Scholar for published literature since December 2019 until September 2020. Finally, we selected 35 articles including case reports, case series and letters to editor. Oral manifestations included ulcer, erosion, bulla, vesicle, pustule, fissured or depapillated tongue, macule, papule, plaque, pigmentation, halitosis, whitish areas, hemorrhagic crust, necrosis, petechiae, swelling, erythema, and spontaneous bleeding. The most common sites of involvement in descending order were tongue (38%), labial mucosa (26%), and palate (22%). Suggested diagnoses of the lesions were aphthous stomatitis, herpetiform lesions, candidiasis, vasculitis, Kawasaki‐like, EM‐like, mucositis, drug eruption, necrotizing periodontal disease, angina bullosa‐like, angular cheilitis, atypical Sweet syndrome, and Melkerson‐Rosenthal syndrome. Oral lesions were symptomatic in 68% of the cases. Oral lesions were nearly equal in both genders (49% female and 51% male). Patients with older age and higher severity of COVID‐19 disease had more widespread and sever oral lesions. Lack of oral hygiene, opportunistic infections, stress, immunosuppression, vasculitis, and hyper‐inflammatory response secondary to COVID‐19 are the most important predisposing factors for onset of oral lesions in COVID‐19 patients.

Keywords: aphthous, COVID‐19, gingivostomatitis, manifestation, oral

1. INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a single‐chain RNA virus that is the cause of novel coronavirus disease known as COVID‐19. The most common clinical symptoms are fever, headache, sore throat, dyspnea, dry cough, abdominal pain, vomiting, and diarrhea. Angiotensin converting enzyme 2 (ACE 2) receptor is a known receptor for SARS‐CoV‐2 that is found in the lung, liver, kidney, gastrointestinal (GI) and even on the epithelial surfaces of sweet glands and on the endothelia of dermal papillary vessels. Todate, various cutaneous manifestations of COVID‐19 disease have been described including varicelliform lesions, pseudochilblain, erythema multiforme (EM)‐liker lesions, urticaria form, maculopapular, petechiae and purpura, mottling, and livedo reticularis‐like lesions. 1 , 2

At the beginning of COVID‐19 pandemic, it was assumed that lack of oral involvement is a differentiating feature of COVID‐19 exanthema relative to other viral exanthemas. Recently, SARS‐CoV‐2 has been detected from saliva of the patients and it has been demonstrated that reverse transcriptase‐polymerase chain reaction (RT‐PCR) from saliva can even be a more sensitive test in comparison with nasopharyngeal test. Furthermore, ACE2 has been found in oral mucosa, especially with more density on dorsum of tongue and salivary glands relative to buccal mucosa or palates. To date, there is only one systematic review that described oral manifestations of COVID‐19 disease; however, it mostly focused on impairment of taste. Dysgeusia is the first recognized oral symptom of COVID‐19 reported in 38% of patients, mostly in North Americans and Europeans, females, and patients with mild‐moderate disease severity. 1 In this review article, we described oral lesions of COVID‐19 patients.

2. METHODS

We searched PubMed library and Google Scholar for published literature using keywords “COVID‐19” or “SARS‐CoV‐2” or “coronavirus disease 2019” AND “oral” OR “buccal mucosa” in the abstract or title since December 2019 until September 2020. We also searched related articles in the reference lists of the found articles. Finally, we selected 35 articles after deletion of non‐English literature and opinion articles.

3. RESULTS

Oral manifestations included ulcer, erosion, bulla, vesicle, pustule, fissured or depapillated tongue, macule, papule, plaque, pigmentation, halitosis, whitish areas, hemorrhagic crust, necrosis, petechiae, swelling, erythema, and spontaneous bleeding. The most common sites of involvement in descending order were tongue (38%), labial mucosa (26%), palate (22%), gingiva (8%), buccal mucosa (5%), oropharynx (4%), and tonsil (1%). Suggested diagnoses of the lesions were aphthous stomatitis, herpetiform lesions, candidiasis, vasculitis, Kawasaki‐like, EM‐like, mucositis, drug eruption, necrotizing periodontal disease, angina bullosa‐like, angular cheilitis, atypical Sweet syndrome, and Melkerson‐Rosenthal syndrome. Oral lesions were symptomatic (painful, burning sensation, or pruritus) in 68% of the cases. Oral lesions were nearly equal in both genders (49% female, 51% male). Latency time between appearance of systemic symptoms and oral lesions was between 4 days before up to 12 weeks after onset of systemic symptoms. In three cases, oral lesions preceded systemic symptoms and in four cases oral and systemic symptoms appeared simultaneously. The longest latency period belonged to Kawasaki‐like lesions. Oral lesions healed between 3 and 28 days after appearance. Different types of therapies including chlorhexine mouthwash, nystatin, oral fluconazole, topical or systemic corticosteroids, systemic antibiotics, systemic acyclovir, artificial saliva, and photobiomodulation therapy (PBMT) were prescribed for oral lesions depends on the etiology 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 . The results of literature are summarized in Table 1.

TABLE 1.

Clinical and laboratory characteristics of patients with oral manifestations

First name author Age Sex Underlying disease Cutaneous Oral Oral Symptom Site Duration (days) Systemic manifestations Latency (days) COVID‐19 Suggested etiology Treatment Lab tests
Verdoni 28

7/5

(2/9‐16)Y

M = 7

F = 3

MP

Acral swelling

NA

Lip

Oral cavity

(80%)

Fever

Diarrhea

Conjunctivitis

Meningeal sign

lymphadenopathy

20%

+

(PCR)

80%

(IgG)

30%

(IgM)

Kawasaki‐like
Jones 29 6 M F

MP

Acral swelling

Cracked lip

Prominent papilla in tongue

Lip

Tongue

Fever

Conjunctivitis

Tachypnea

2

+

(PCR)

Kawasaki‐like

IVIG

ASA

Increased levels of CRP, ESR

Hypoalbuminemia

Pouletty 30

10

(4/7‐12/5)Y

M = 8

F = 8

Over weight

Asthma

Rash

Cracked lip (87%)

Lip

Fever

Respiratory &

GI symptom

Anosmia

69%

+

(PCR)

Kawasaki‐like

IVIG

CS

ANTI IL1, IL6

HCH

Increased levels of cardiac markers

Increased levels of CRP, ESR

Lymphocytopenia

Singh 19 44Y M

DM

HTN

Non blanch able erythema Necrosis Extensive mucosal damage

Lip

Tongue

Malaise

Dyspnea

4 Vascular inflammation Ischemic reperfusion injury
Chiotos 31 5Y F

Fissured lip

Lip

Fever

Diarrhea

Conjunctivitis

Kawasaki‐like

IVIG

Thrombocytopenia

Increased levels of cardiac marker

Chiotos 31 9Y F

Fissured lip

Straw berry tongue

Lip

Tongue

Fever

Diarrhea

Conjunctivitis

+

(PCR)

Kawasaki‐like

IVIG

ASA

CS

Increased levels of CRP, ESR

Chiotos 31 12Y M Fissured lip Lip

Fever

Abdominal pain

Diarrhea

(−)

(PCR)

Kawasaki like

IVIG

Milrinone

Increased levels of Cardiac marker

Increased levels of CRP, ESR

Chiu 32 10Y M

Cracked lip

Erythema

Lip

Oropharynx

Fever

Cough

Diarrhea

Conjunctivitis

+

(PCR)

Kawasaki‐like Dopamine

Leukocytosis

Lymphocytopenia

Increased levels of CRP, ESR, D‐dimer, Procalcitonin

Increased levels of Cardiac markers

Mazzotta 26 9Y M

Urticaria

Angioedema

Acral edema

Glossitis

Cheilitis

Painful

Fever

Cough

Diarrhea

Conjunctivitis

28‐84

+

(Ig G)

Kawasaki‐like CS

Indu 13

NS M Ulcer

Burning

Itching

Painful

Lip

Tongue

10 Fever −4

+

(PCR)

Zosteriform
Taşkın 25 61Y F Nodules Minor aphthous ulcer

Hard palate

Buccal

Fever

Fatigue

Myalgia

Arthralgia

+

(PCR)

Atypical Sweet syndrome

AZT

HCH

Oseltamivir

Tocilizomab

Favipiravir

Increased levels of CRP, ESR, D‐dimer

Leukocytosis

Taşlıdere 24 51Y F

Swollen lip

Fissured tongue

Lip

Tongue

Malaise

Unilateral Facial paralysis

Facial edema

Coincident MRS

HCH

AZT

CS

Increased levels of CRP

Negative Serology for HSV, CMV,EBV, coxsackie

Ground glass opacity in CT scan

Brandão 7 28Y M

Aphthous‐like

Ageusia

Lip

Tongue

6

Fever

Cough

Headache

Myalgia

Chills

Anosmia

8

+

(PCR)

Mouthwash
Brandão 7 29Y M

Aphthous‐like

Ageusia

Painful

Tongue

5

Cough

Dyspnea

Fever

Malaise

Headache

Anosmia

8

+

(PCR)

Ipratropium bromide

Fenoterol hydrochloride

Brandão 7 35Y M Aphthous‐like

Tonsil

8

Fever

Malaise

Sore throat

Cough

Hyposmia

Ageusia

Odynophagia

6

+

(PCR)

Brandão 7

32Y

F Aphthous ‐like

Tongue

5

Dysgeusia

Fever

Cough

Headache

Anosmia

10

+

(PCR)

Dipyrone
Brandão 7 72Y M

HTN

DM

Aphthous‐like

Necrosis

Hemorrhagic ulcer

painful Lip 7

Fever

Dyspnea

5

+

(PCR)

P/T

AZT

Ceftriaxone

Acyclovir

PBM

Increased levels of CRP

Lymphocytopenia

Positive PCR for HSV

Brandão 7 83Y F

HTN

COPD

Obesity

Parkinson

Pancreatitis

Aphthous‐like

Petechiae

Necrosis

painful

Tongue

Hard palate

5 2

+

(PCR)

Ceftriaxone

PBMT

P/T

Negative PCR for HSV

Lymphocytopenia

Brandão 7 71Y F

HTN

DM

CRF

Obesity

Aphthous‐like

Hemorrhagic necrosis

Ulcer

painful

Tongue

Lip

15

Fever

Cough

Dyspnea

4

+

(PCR

AZT

Ceftriaxone

Acyclovir

PBMT

Positive PCR for HSV

Brandão 7 81Y M

HTN

COPD

Aphthous‐like

Necrosis

Hemorrhagic ulcer

painful

Lip

Tongue

11

Dry Cough

Dyspnea

Fever

Chills

Dysgeusia

5

+

(PCR)

AZT

Ceftriaxone

Acyclovir

PBMT

Increased levels of CRP

Ground glass opacity in CT scan

Positive PCR for HSV

Malih 8 38Y M MP Erythema Aphthous‐like Painful tonsil

Fever

Fatigue

Myalgia

Loss of taste and smell

3

+

(PCR)

Acetaminophen
Labé 22 3Y M

Exanthema

Palmar edema

Cheilitis

Glossitis

Stomatitis

Lip

Tongue

Oral cavity

Fever

Asthenia

Cervical LAP

Kawasaki‐like IVIG

Increased levels of CRP

Leukocytosis

Ground glass opacity in CT scan

Labé 22 6Y M Target lesions

Erosion Cheilitis

Hemorrhagic crust

painful

Lip

Gingiva

21 Loss of appetite 7

+

(PCR)

EM like Negative serology for mycoplasma Negative PCR for HSV
Aghazadeh 9 9Y F Papule Plaque

Vesicles

Erosions

Lip

Tongue

Buccal

7

Fever

Weakness

Loss of appetite

Abdominal pain

Diarrhea

Coincident

+

(PCR)

Herpetiform

Acetaminophen

Bilateral ground glass opacity
Kämmerer 10 46Y M

HLP

CAD

Multiple ulceration covered by yellow gray membrane

Painful

Oral cavity

Gingiva

Fever

Fatigue

Dry cough

Respiratory distress

LAP submandibular

5 days after intubation

+

(PCR)

Secondary herpetic Gingivostomatitis

AZT

Meropenem

Acyclovir

Increased levels of CRP, IL6,

Eosinopenia

Positive PCR for HSV

Positive serology for HSV(IgM)

Bilateral ground glass opacity in CT scan

Cruz Tapia 23 42Y M _ _ Macules Burning Hard palate 7

Fever

Malaise

Dysgeusia

Headache

14

+

(PCR)

Mucositis due to vasculitis and thrombosis

Acetaminophen

Mouthwash

CS

_
Cruz Tapia 23 55Y F

Tongue enlargement

Purple blister

Tongue 5

Fever

Headache

Nasal congestion

2

+

(PCR)

Angina bullosa‐like

Acetaminophen

Cruz Tapia 23 51Y F HTN _

Vascular‐like purple macule nonbleeding Purple plaque

Palate

Fever

Malaise

Dysgeusia

Arthralgia

+

(PCR)

Vascular disorder

CS

AZT

NSAID

Cruz Tapia 23 41Y F _ _ Erythematous blister Hard palate

Fever

Malaise

Dysgeusia

Hyposmia

+

(PCR)

Angina‐bullosa‐like

Acetaminophen

Fexofenadine

Díaz Rodríguez 6 78Y F

Dry mouth

Atrophy of surface of tongue

White & red patches

Fissured tongue

Tongue Hard Palate

Soft palate

Lip

15

+

(PCR)

Pseudomembranous candidiasis Angular cheilitis due to Stress

Immunosuppression

Artificial saliva

Nystatin

Neomycin

CS

Díaz Rodríguez 6 53Y M Angular cheilitis Burning

Lip

10

Dysgeusia

Anosmia

Few days after discharge

+

(PCR)

Cheilitis due to stress and immunosuppression

Nystatin

CS

Neomycin,

Mouthwash

Díaz Rodríguez 6 43Y F

Multiple ulcer covered by yellow‐gray membrane

Lingual depapillation

Burning

Tongue

10

Fever

Malaise

Dysgeusia

Anosmia

Diarrhea

Pneumonia

14

+

(PCR)

Aphthous‐like due to stress and immunosuppression

Mouthwash

CS

Chérif 27 35Y F Macule

Chapped lips

Ulcer

Hypogeusia

Tongue

Lip

10

Fever

Myalgia

Dyspnea

Dry cough

Vomiting

Diarrhea

+

(PCR)

Kawasaki‐like

HCH

AZT

Cefuroxime

Thrombocytopenia Anemia

Neutrophilia

Lymphopenia

Increased levels of liver and cardiac markers

Increased levels of CRP,LDH,

ferritin

Ansari 18 75Y M HTN Irregular ulcer in erythematous background Painful

Tongue

(anterior)

7 Hypoxia 7

+

(PCR)

Mucosal ulcer due to COVID‐19

AZT,

Mouthwash

Negative Serology for HSV 1‐2
Ansari 18 56Y F DM Irregular ulcer in erythematous background Painful Hard palate 7

Fever

Dyspnea

4

+

(PCR)

Mucosal ulcer due to COVID‐19

Remidisivir

AZT

Negative Serology for HSV 1–2
Biadsee 3 36.25Y NS

HTN

DM

Hypothyroidism

Asthma

Plaque bleeding

Swelling Xerostomia Dysgeusia

Tongue

Palate

Gingiva

Fever

Cough

Myalgia

Sore throat

Anosmia

GI symptoms

+

(PCR)

Olisova 11 12Y F

Purpura

Macule

Swollen,

Irritated

Pronounced lingual papilla

Tongue

3

Fever

Fatigue

Headache

3

+

(PCR)

Paracetamol Increased levels of ESR CRP
Tomo 36 37Y F Erythema Depapillation of tongue Painful

Tongue

(border)

14

Fever

Asthenia

Dysgeusia

Anosmia

9

+

(PCR)

Mucositis due to hypersensitivity to SARS‐CoV‐2

CS

Dipyrone

Mouthwash

Ciccarese 17 19Y F

Macules

Papules

Petechiae

Erosion

Ulcer

Hemorrhagic crust

Petechial

Lip

Palatal

Gingival

Oropharynx

5

Fever

Fatigue

Hyposmia

Sore throat

7

+

(PCR)

Thrombocytopenia due to COVIDS‐19 and cefixime

IVIG

CS

Thrombocytopenia

Leukocytosis

Increased levels of liver markers and LDH

Sakaida 16 52Y F

MP

Petechiae

Erosion

Lip

Buccal

Fever

Dyspnea

Dry cough

−3

+

(PCR)

Drug eruption

NSAID

Clarithromycin

SAM

Levofloxacin

Cs

Leukocytosis

Lymphopenia

Neutrophilia

Increased level of CRP

Dominguez‐Santas 37 19Y M

Minor aphthous

Lip

Fever

Headach

Anosmia

Malaise

dyspnea

0

+

(PCR)

Cytokine storm due to COVID‐19

Lymphocytopenia

Negative PCR for HSV

Negative serology for syphilis,

HIV, EBV,

CMV, HBV,

HCV

Dominguez‐Santas 37 37Y M

Minor aphthous

Tongue

5

+

(PCR)

Cytokine storm due to COVID‐19

Lymphocytopenia

Negative PCR for HSV

Negative serology for syphilis,

HIV, EBV,

CMV, HBV,

HCV

Dominguez‐Santas 37 33Y M

Minor aphthous

Mucogingivl

junction

Pneumonia

Fever

Malaise

3

+

(PCR)

Cytokine storm due to COVID‐19

Lymphocytopenia

Negative PCR for HSV

Negative serology for syphilis,

HIV, EBV,

CMV, HBV,

HCV

Dominguez‐Santas 37 43Y F

Minor aphthous

Buccal

Bilateral pneumonia Fever

Malaise

4

+

(PCR)

Cytokine storm due to COVID‐19

Lymphocytopenia

Negative PCR for HSV

Negative serology for syphilis,

HIV, EBV,

CMV, HBV,

HCV

Putra 5 29Y M _ Papule Aphthous Stomatitis

Fever

Myalgia

sore throat

Dry cough

6

+

(PCR)

Enanthema due to COVID‐19

Paracetamol

AZT

HCH

Oseltamivir

Vitamin C

Vitamin D

Increase level of CRP
Martín Carreras‐Presas 12 65Y F

HTN

Obesity

Rash Desquamative gingivitis Painful

Tongue

Gingiva

28

Fever

Diarrhea

25

+

(serology)

EM‐like

Antibiotic

CS

HCH

HA

L/R

Martín Carreras‐Presas 12 58Y M

DM

HTN

Unilateral multiple small ulcers Painful

Palate

7 Herpetiform Mouthwash
Martín Carreras‐Presas 12 56Y M Dysgeusia, Herpetiform Stomatitis Painful

Hard Palate

10

Fever Asthenia

LAP

2 NP Herpetiform

Val acyclovir

Mouthwash

HA

Jimenez‐Cauhe 21 60Y

M = 2

F = 4

EM‐like

Macule Petechiae

Palate 19 Enanthema due to COVID‐19

AZT

HCH

L/R

Jimenez‐Cauhe 21 40Y

Purpura

EM‐like

Petechiae

Macule Petechiae

Palate

Palate

2

24

Enanthema due to COVID‐19

Enanthema due to COVID‐19

L/R

HCH

AZT

T

CS

L/R

HCH

AZT

Tocilizomab

CS

Thrombocytopenia

High

D‐dimer

High D‐dimer

Jimenez‐Cauhe 21 50Y
Jimenez‐Cauhe 21 60Y EM‐like

Macule Petechiae

Palate

19

+

(PCR)

Enanthema due to COVID‐19

L/R

HCH

AZT

High D‐dimer
Jimenez‐Cauhe 21 60Y

Papule

Vesicle

Petechiae

Palate

−2

+

(PCR)

Enanthema due to COVID‐19

L/R

HCH

AZT

High D‐dimer
Jimenez‐Cauhe 21 40Y purpura Macule Palate 12

+

(PCR)

Enanthema due to COVID‐19

L/R

HCH

Thrombocytopenia

High

D‐dimer

Patel 33 35Y F _ _

Bleeding

Halitosis

Generalized edematous erythematous gingiva

Necrosis

Painful

Gingiva

5

Fever

LAP submandibular

3 NP Bacterial co‐infection

Metronidazole

Mouthwash

_
Chaux‐Bodard 14 45 Y F Patch

Ulcer

Painful

Tongue

(dorsal)

10

Asthenia

+

(PCR)

Vasculitis
Soares 15 42Y M

DM

HTN

Petechiae

Vesicle

Blister

Ulcer

Macules

Painful

Buccal

Tongue

Lip

Hard Palate

21

Fever

Cough

Dyspnea

+

(PCR)

Thrombotic vasculopathy due to SARS –CoV‐2

CS

Dipyrone

IHC: negative for other viral and trepnema palladium
dos Santos 4 67Y M

CAD

HTN

PCK

RT

White plaque Multiple yellowish ulcer Geographic tongue

Erythema Hypogeusia

Tongue

Palate

Tonsil

14

Fever

Diarrhea

Dyspnea

24

+

(PCR)

Herpetiform lesions secondary to determination of systemic health and treatment

Mouthwash

Fluconazole

Nystatin

AZT

Ceftriaxone

HCH

Meropenem

T/S

Positive Culture for +Saccharomyces cerevisiae
Corchuelo 20 40Y F

Petechiae

Whitish area

Brown pigmentation

Painful

Tongue

Lip

Gingiva

20

LAP of neck

+

(IgG)

Candidiasis

Thrombocytopenia due to ibuprofen

PIH

Ibuprofen

Vitamin D

AZT

Mouthwash

Nystatin

Jimenez‐Cauhe 35 66.7(58‐77)Y F = 3 _ EM‐like

Petechiae

Macule

Palate 14‐21 _

19.5

(16‐24)

_ EM‐Like

AZT

Ceftriaxone

Cs

HCH

L/R

Increase levels of CRP

High

D‐dimer

Lymphocytopenia

Negative serology for syphilis, M. Pneumonia and other viral

Cebeci Kahraman 34 51Y M _ _

Large erythematous

Petechiae

Pustules

Painful

Hard palate

Oropharynx

Soft palate

Ageusia

A few days

Fever

Fatigue

Dry cough

Sore throat

Anosmia

10

+

(IgM)

Enanthema due to COVID‐19 Clarithromycin

Abbreviations: AZT, azithromycin; CAD, chronic arterial disease; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; DM, diabetes mellitus; HCH, hydroxychloroquine; HLP, hyperlipidemia; HTN, hypertension; L/EX, lower extremity; M, month; MP, maculopapular; MRS, Melkersson‐Rosenthal syndrome; P/T, piperacillin/tazobactam; PCK, poly cystic kidney; PIH, postinflammatory hyperpigmentation; RT, renal transplantation; SAM, ampicillin sulbactam; T/S, trimethoprim/sulfamethoxazole; Y, year.

4. DISCUSSION

Enanthema can develop in various types of viral diseases including dengue fever disease, Ebola virus disease, herpangina, human herpes virus (HHV) infections, measles, and roseola infantum. Infectious diseases, especially of viral etiology, constitute approximately 88% of causes of enanthema. Different types of enanthema such as aphthous‐like ulcers, Koplik's spots, Nagayama's spot, petechiae, papulovesicular, or maculopapular lesions, white or red patches, gingival and lip swelling have been reported with various viral infections. Both keratinized (hard palate, gingiva, and dorsum of tongue) and nonkeratinized (labial and buccal) mucosae can be involved. 38 Biadsee and colleagues demonstrated that 7% of the patients with RT‐PCR positive test had plaque‐like changes on the dorsum of tongue. Also, swelling of oral cavity (including palatal, lingual, and gum) was reported by 8% of the patients. Furthermore, appearance of oral lesions was simultaneously found with loss of taste and smell in the patients and more severe and disseminated oral lesions were reported in older patients and in severe COVID‐19. 3 In another study, enanthema was reported in 29% of cases with confirmed COVID‐19 and cutaneous exanthema. 35

4.1. Aphthous‐like lesions

Aphthous‐like lesions appeared as multiple shallow ulcers with erythematous halos and yellow‐white pseudomemberanes on the both keratinized and nonkeratinized mucosae. In one patient, oral lesions appeared simultaneously with systemic symptoms and in other patients, latency time was between 2 and 10 days. One patient had positive history of recurrent aphthous stomatitis (RAS) and two patients had positive PCR for herpes simplex virus (HSV). 4 , 5 , 6 , 7 , 8 , 37 Aphthous‐like lesions without necrosis were observed in younger patients with mild infection, whilst aphthous‐like lesions with necrosis and hemorrhagic crusts were observed more frequently in older patients with immunosuppression and severe infection. Lesions healed after 5 to 15 days. 7 Regression of oral lesions was in parallel association with improvement of systemic disease. Increased level of tumor necrosis factor (TNF)‐α in COVID‐19 patients can lead to chemotaxis of neutrophils to oral mucosa and development of aphthous‐like lesions. Stress and immunosuppression secondary to COVID‐19 infection could be other possible reasons for appearance of such lesions in COVID‐19 patients. 4

4.2. Herpetiform/zosteriform lesions

Herpetiform lesions presented as multiple painful, unilateral, round yellowish‐gray ulcers with an erythematous rim on the both keratinized and nonkeratinized mucosae. Manifestations of these lesions preceded, coincided with, or followed systemic symptoms. In one case, geographic tongue appeared after recovery of herpetiform lesions. Stress and immunosuppression associated with COVID‐19 was the suggested cause for appearance of secondary herpetic gingivostomatitis. 4 , 9 , 10 , 12 , 13

4.3. Ulcer and erosion

Ulcerative or erosive lesions appeared as painful lesions with irregular borders on the tongue, hard palate, and labial mucosa. Lesions appeared after a latency time of 4 to 7 days and in one case, lesions appeared 3 days before the onset of systemic symptoms and recovered after 5 to 21 days. In two cases, PCR for HSV‐1 and HSV‐2 was performed and was negative. Different factors including drug eruption (to NSAID in one case), vasculitis, or thrombotic vasculopathy secondary to COVID‐19 were suggested as causes for development of ulcerative and erosive lesions. 14 , 15 , 16 , 17 , 18 , 19

4.4. White/red plaques

White and red patches or plaques were reported on dorsum of tongue, gingiva, and palate of patients with confirmed or suspected COVID‐19. Candidiasis due to long‐term antibiotic therapy, deterioration of general status, and decline in oral hygiene can be the cause of white or red patches or plaques. 4 , 6 , 20

4.5. EM‐like lesions

EM‐like lesions appeared as blisters, desquamative gingivitis, erythematous macules, erosions, and painful cheilitis with hemorrhagic crust in patients with cutaneous target lesions in the extremities. Lesions appeared between 7 and 24 days after the onset of systemic symptoms and recovered after 2 to 4 weeks. 12 , 21 , 22

4.6. Angina bullosa‐like lesions

Angina bullosa‐like lesions presented as asymptomatic erythematous‐purple blisters without spontaneous bleeding on the tongue and hard palate in two confirmed cases of COVID‐19. 23

4.7. Melkerson‐Rosenthal syndrome

There was a report of a 51‐year‐old woman presenting with complaint of malaise and unilateral lip swelling, fissured tongue and right facial paralysis. She had past history of Melkersson‐Rosenthal syndrome since 4 years ago that was spontaneously cured with no relapse. Laboratory data demonstrated an increased level of CRP and computed tomography (CT) scan showed ground‐glass opacities in both lungs. The patient cured completely after treatment of COVID‐19 disease. 24

4.8. Atypical sweet syndrome

There was a report of 61‐year‐old female who presented complaining of fever, fatigue, arthralgia, myalgia, several erythematous nodules on the scalp, trunk and extremities, and minor aphthous ulcers on the hard palate and buccal mucosa. RT‐PCR for COVID‐19 was positive. Skin biopsy showed diffuse neutrophilic infiltration in the upper dermis with granulomatous infiltration in the lower dermis and subcutaneous area that was compatible with erythema nodosum‐like Sweet syndrome. 25

4.9. Kawasaki‐like disease

Oral lesions including cheilitis, glossitis, and erythematous and swollen tongue (red strawberry tongue) appeared in COVID‐19 patients with Kawasaki‐like disease (Kawa‐COVID). The long duration of latency between appearance of systemic symptoms (respiratory or gastrointestinal) and onset of oral or cutaneous symptoms could be due to a delayed hyperactivation response of the immune system and secondary release of acute inflammatory cytokines rather than direct effects of virus on the skin and oral mucosa. 22 , 26 , 27 , 28 , 29 , 30 , 31 , 32

4.10. Necrotizing periodontal disease

There was a report of a 35‐year‐old female suspicious for COVID‐19 who presented with fever, submandibular lymphadenopathy, halitosis, and oral lesions. Oral lesions included a painful, diffuse erythematous and edematous gingiva with necrosis of inter‐papillary areas. The suggested diagnosis was necrotizing periodontal disease due to bacterial coinfections (especially prevotella intermedia) along with COVID‐19. The lesions recovered after 5 days. 33

4.11. Vesicles and pustules

We found a report of a 9‐year‐old female presenting with fever, weakness, abdominal pain, and diarrhea that coincided with oral and acral erythematous papular exanthema. Oral lesions included vesicular eruptions and erosions on the tongue and buccal mucosa. PCR test for COVID‐19 was positive. Lesions cured after 1 week. 9

There was also another report on a 51‐year‐old male presented with fever, fatigue, dry cough, dysgeusia, anosmia, and a positive serology for COVID‐19. After 10 days, widespread erythema appeared on hard palate and oropharynx with petechiae and pustules on soft palate border. The suggested diagnosis was enanthema due to COVID‐19 and the lesions cured after a few days. 34

4.12. Petechiae

In a few studies, Petechiae were reported on the lower lip, palate, and oropharynx mucosa. Latency time for patients with petechiae was shorter compared to the patients with both petechiae and macular lesions. Thrombocytopenia due to COVID‐19 infection or the prescribed drug were suggested as possible causes of petechiae. 20 , 21 , 34 , 35

4.13. Nonspecific lesions (mucositis)

Erythematous‐violaceous macules, patches, papules and plaques on the tongue, lip mucosa, hard palate, and oropharynx were reported in several studies. Thrombotic vasculopathy, vasculitis, hypersensitivity associated to COVID‐19 could be the causes of mucositis in patients with COVID‐19. Mucosal hypersensitivity secondary to COVID‐19, thrombotic vasculopathy, and vasculitis might be the possible causes of mucositis in COVID‐19. 8 , 15 , 21 , 23 , 34 , 35 , 36

4.14. Postinflammatory pigmentation

There was one report of pigmentation in the attached and interpapillary gingiva in a 40‐year‐old female. Increased levels of inflammatory cytokines (including interleukin‐1 [IL‐1], tumor necrosis factor [TNF]‐α) and arachidonic acid metabolites (prostaglandins) secondary to production of stem cell factor (SCF) and basic‐fibroblast growth factor (bFGF) from keratinocytes of basal layer lead to postinflammatory pigmentations. 20

5. CONCLUSION

Aphthous‐like lesions, herpetiform lesions, candidiasis, and oral lesions of Kawasaki‐like disease are the most common oral manifestations of COVID‐19 disease. An older age and severity of COVID‐19 disease seem to be the most common factors that predict severity of oral lesions in these patients. Lack of oral hygiene, opportunistic infections, stress, underling diseases (diabetes mellitus, immunosuppression), trauma (secondary to intubation), vascular compromise, and hyper‐inflammatory response secondary to COVID‐19 might be are the most important predisposing factors for the development of oral lesions in COVID‐19 patients.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

Behzad Iranmanesh, Maryam Khalili, Rezvan Amiri, and Mahin Aflatoonian contributed to the study conception and design. Material preparation, data collection, were performed by Behzad Iranmanesh, Maryam Khalili, Rezvan Amiri, Hamed Zartab, and Mahin Aflatoonian The first draft of the manuscript was written by Behzad Iranmanesh and Mahin Aflatoonian and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Iranmanesh B, Khalili M, Amiri R, Zartab H, Aflatoonian M. Oral manifestations of COVID‐19 disease: A review article. Dermatologic Therapy. 2021;34:e14578. 10.1111/dth.14578

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

REFERENCES

  • 1. Seirafianpour F, Sodagar S, Pour Mohammad A, et al. Cutaneous manifestations and considerations in COVID‐19 pandemic: a systematic review. Dermatol Ther. 2020;e13986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Amorim dos Santos J, Normando AG, Carvalho da Silva RL, et al. Oral manifestations in patients with COVID‐19: a living systematic review. J Dent Res. 2020;0022034520957289. [DOI] [PubMed] [Google Scholar]
  • 3. Biadsee A, Biadsee A, Kassem F, Dagan O, Masarwa S, Ormianer Z. Olfactory and oral manifestations of COVID‐19: sex‐related symptoms—a potential pathway to early diagnosis. Otolaryngol Head Neck Surg. 2020:163(4):722‐8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. dos Santos JA, Normando AG, da Silva RL, et al. Oral mucosal lesions in a COVID‐19 patient: new signs or secondary manifestations? Int J Infect Dis. 2020;9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Putra BE, Adiarto S, Dewayanti SR, Juzar DA. Viral Exanthem with “pin and needles sensation” on extremities of COVID‐19 patient. Int J Infect Dis. 2020;96:355‐358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Díaz Rodríguez M, Jimenez Romera A, Villarroel M. Oral manifestations associated with COVID‐19. Oral Dis. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Brandão TB, Gueiros LA, Melo TS, et al. Oral lesions in patients with SARS‐CoV‐2 infection: could the oral cavity be a target organ? Oral Surg Oral Med Oral Pathol Oral Radiol. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Malih N, Hajinasrollah G, Zare M, Taheri M. Unexpected presentation of COVID‐19 in a 38‐year‐old male patient: a case report. Case Rep Dermatol. 2020;12(2):124‐131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Aghazadeh N, Homayouni M, Sartori‐Valinotti JC. Oral vesicles and acral erythema: report of a cutaneous manifestation of COVID‐19. Int J Dermatol. 2020;59(9):1153‐1154. [DOI] [PubMed] [Google Scholar]
  • 10. Kämmerer T, Walch J, Flaig M, French LE. COVID‐19 associated herpetic gingivostomatitis. Clin Exp Dermatol. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Olisova OY, Anpilogova EM, Shnakhova LM. Cutaneous manifestations in COVID‐19: a skin rash in a child. Dermatol Ther. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Martín Carreras‐Presas C, Amaro Sánchez J, López‐Sánchez AF, Jané‐Salas E, Somacarrera Pérez ML. Oral vesiculobullous lesions associated with SARS‐CoV‐2 infection. Oral Dis. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Indu S. Multiple oral ulcerations–an initial manifestation of COVID 19 infection: a personal experience. J Oral Maxillofac Pathol. 2020;24(2):227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Chaux‐Bodard AG, Deneuve S, Desoutter A. Oral manifestation of Covid‐19 as an inaugural symptom? J Oral Med Oral Surg. 2020;26(2):18. [Google Scholar]
  • 15. Soares CD, de Carvalho RA, de Carvalho KA, de Carvalho MG, de Almeida OP. Letter to editor: oral lesions in a patient with Covid‐19. Med Oral Patol Oral Cir Bucal. 2020;25(4):e563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Sakaida T, Isao T, Matsubara A, Nakamura M, Morita A. Unique skin manifestations of COVID‐19: is drug eruption specific to COVID‐19? J Dermatol Sci. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Ciccarese G, Drago F, Boatti M, Porro A, Muzic SI, Parodi A. Oral erosions and petechiae during SARS‐CoV‐2 infection. J Med Virol. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Ansari R, Gheitani M, Heidari F, Heidari F. Oral cavity lesions as a manifestation of the novel virus (COVID‐19): a letter‐to‐editor. Oral Dis. 2020. [DOI] [PubMed] [Google Scholar]
  • 19. Singh C, Tay J, Shoqirat N. Skin and mucosal damage in patients diagnosed with COVID‐19: a case report. J Wound Ostomy Continence Nurs. 2020;47(5):435‐438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Corchuelo J, Ulloa FC. Oral manifestations in a patient with a history of asymptomatic COVID‐19. Case Report Int J Infect Dis. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Jimenez‐Cauhe J, Ortega‐Quijano D, Carretero‐Barrio I, et al. Erythema multiforme‐like eruption in patients with COVID‐19 infection: clinical and histological findings. Clin Exp Dermatol. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Labé P, Ly A, Sin C, et al. Erythema multiforme and Kawasaki disease associated with COVID‐19 infection in children. J Eur Acad Dermatol Venereol. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Cruz Tapia RO, Peraza Labrador AJ, Guimaraes DM, Matos Valdez LH. Oral mucosal lesions in patients with SARS‐CoV‐2 infection. Report of four cases. Are they a true sign of COVID‐19 disease? Spec Care Dentist. 2020;40(6):555‐60. [DOI] [PubMed] [Google Scholar]
  • 24. Taşlıdere B, Mehmetaj L, Özcan AB, Gülen B, Taşlıdere N. Melkersson‐Rosenthal syndrome induced by COVID‐19: a case report. Am J Emerg Med. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Taşkın B, Vural S, Altuğ E, et al. COVID‐19 presenting with atypical Sweet's syndrome. J Eur Acad Dermatol Venereol. 2020;34:e534‐e535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Mazzotta F, Troccoli T, Caselli D, Bonifazi E. Acral rash in a child with COVID‐19. Eur J Pediat Dermatol. 2020;30(2):79‐82. [Google Scholar]
  • 27. Chérif MY, de Filette JM, André S, Kamgang P, Richert B, Clevenbergh P. Coronavirus disease 2019‐related Kawasaki‐like disease in an adult: a case report. JAAD Case Rep. 2020;6(8):780‐782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki‐like disease at the Italian epicentre of the SARS‐CoV‐2 epidemic: an observational cohort study. The Lancet. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Jones VG, Mills M, Suarez D, et al. COVID‐19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr. 2020;10(6):537‐540. [DOI] [PubMed] [Google Scholar]
  • 30. Pouletty M, Borocco C, Ouldali N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS‐CoV‐2 mimicking Kawasaki disease (Kawa‐COVID‐19): a multicentre cohort. Ann Rheum Dis. 2020;79:999‐1006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Chiotos K, Bassiri H, Behrens EM, et al. Multisystem inflammatory syndrome in children during the COVID‐19 pandemic: a case series. J Pediat Infect Dis Soc. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Chiu JS, Lahoud‐Rahme M, Schaffer D, Cohen A, Samuels‐Kalow M. Kawasaki disease features and myocarditis in a patient with COVID‐19. Pediatr Cardiol. 2020;41(7):1526‐8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Patel J, Woolley J. Necrotizing periodontal disease: oral manifestation of COVID‐19. Oral Dis. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Cebeci Kahraman F, ÇaŞkurlu H. Mucosal involvement in a COVID‐19‐positive patient: a case report. Dermatol Ther. 2009;14(6):E272‐7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Jimenez‐Cauhe J, Ortega‐Quijano D, de Perosanz‐Lobo D, et al. Enanthem in patients with COVID‐19 and skin rash. JAMA Dermatol. 2020;156(10):1134‐6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Tomo S, Miyahara GI, Simonato LE. Oral mucositis in a SARS‐CoV‐2‐infected patient: secondary or truly associated condition? Oral Dis. 2020. [DOI] [PubMed] [Google Scholar]
  • 37. Dominguez‐Santas M, Diaz‐Guimaraens B, Fernandez‐Nieto D, Jimenez‐Cauhe J, Ortega‐Quijano D, Suarez‐Valle A. Minor aphthae associated with SARS‐CoV‐2 infection. Int J Dermatol. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Rocha BA, Souto GR, de Mattos Camargo Grossmann S, et al. Viral enanthema in oral mucosa: a possible diagnostic challenge in the COVID‐19 pandemic. Oral Dis. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.


Articles from Dermatologic Therapy are provided here courtesy of Wiley

RESOURCES